Literature DB >> 25132466

Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia.

Jan Harry Cabungcal1, Danielle S Counotte2, Eastman Lewis3,2, Hugo A Tejeda3,2, Patrick Piantadosi2, Cameron Pollock2, Gwendolyn G Calhoon3,2, Elyse Sullivan3,2, Echo Presgraves2, Jonathan Kil4, L Elliot Hong3,5,6, Michel Cuenod1, Kim Q Do1, Patricio O'Donnell3,2,5.   

Abstract

Abnormal development can lead to deficits in adult brain function, a trajectory likely underlying adolescent-onset psychiatric conditions such as schizophrenia. Developmental manipulations yielding adult deficits in rodents provide an opportunity to explore mechanisms involved in a delayed emergence of anomalies driven by developmental alterations. Here we assessed whether oxidative stress during presymptomatic stages causes adult anomalies in rats with a neonatal ventral hippocampal lesion, a developmental rodent model useful for schizophrenia research. Juvenile and adolescent treatment with the antioxidant N-acetyl cysteine prevented the reduction of prefrontal parvalbumin interneuron activity observed in this model, as well as electrophysiological and behavioral deficits relevant to schizophrenia. Adolescent treatment with the glutathione peroxidase mimic ebselen also reversed behavioral deficits in this animal model. These findings suggest that presymptomatic oxidative stress yields abnormal adult brain function in a developmentally compromised brain, and highlight redox modulation as a potential target for early intervention.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25132466      PMCID: PMC4418441          DOI: 10.1016/j.neuron.2014.07.028

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  52 in total

1.  Increased nitric oxide radicals in postmortem brain from patients with schizophrenia.

Authors:  Jeffrey K Yao; Sherry Leonard; Ravinder D Reddy
Journal:  Schizophr Bull       Date:  2004       Impact factor: 9.306

2.  Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia.

Authors:  P Steullet; H C Neijt; M Cuénod; K Q Do
Journal:  Neuroscience       Date:  2005-12-05       Impact factor: 3.590

3.  Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase.

Authors:  Jonathan Kil; Carol Pierce; Huy Tran; Rende Gu; Eric D Lynch
Journal:  Hear Res       Date:  2006-10-06       Impact factor: 3.208

4.  Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene.

Authors:  Mirjana Tosic; Jurg Ott; Sandra Barral; Pierre Bovet; Patricia Deppen; Fulvia Gheorghita; Marie-Louise Matthey; Josef Parnas; Martin Preisig; Michael Saraga; Alessandra Solida; Sally Timm; August G Wang; Thomas Werge; Michel Cuénod; Kim Quang Do
Journal:  Am J Hum Genet       Date:  2006-07-31       Impact factor: 11.025

5.  Apocynin ameliorates cadmium-induced hypertension through elevation of endothelium nitric oxide synthase.

Authors:  Chukwuemeka R Nwokocha; Abena Baker; Damion Douglas; Garsha McCalla; Magdalene Nwokocha; Paul D Brown
Journal:  Cardiovasc Toxicol       Date:  2013-12       Impact factor: 3.231

6.  Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence.

Authors:  René Gysin; Rudolf Kraftsik; Julie Sandell; Pierre Bovet; Céline Chappuis; Philippe Conus; Patricia Deppen; Martin Preisig; Viviane Ruiz; Pascal Steullet; Mirjana Tosic; Thomas Werge; Michel Cuénod; Kim Q Do
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-05       Impact factor: 11.205

7.  Glutathione deficit during development induces anomalies in the rat anterior cingulate GABAergic neurons: Relevance to schizophrenia.

Authors:  Jan-Harry Cabungcal; Dominique Nicolas; Rudolf Kraftsik; Michel Cuénod; Kim Q Do; Jean-Pierre Hornung
Journal:  Neurobiol Dis       Date:  2006-02-14       Impact factor: 5.996

8.  Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase.

Authors:  M Margarita Behrens; Sameh S Ali; Diep N Dao; Jacinta Lucero; Grigoriy Shekhtman; Kevin L Quick; Laura L Dugan
Journal:  Science       Date:  2007-12-07       Impact factor: 47.728

9.  Effects of ebselen on glutathione level in neurons exposed to arachidonic acid and 4-hydroxynonenal during simulated ischemia in vitro.

Authors:  Natalia Pawlas; Andrzej Małecki
Journal:  Pharmacol Rep       Date:  2007 Nov-Dec       Impact factor: 3.024

10.  D2 dopamine receptors recruit a GABA component for their attenuation of excitatory synaptic transmission in the adult rat prefrontal cortex.

Authors:  Kuei Y Tseng; Patricio O'Donnell
Journal:  Synapse       Date:  2007-10       Impact factor: 2.562

View more
  80 in total

Review 1.  Interneuron epigenomes during the critical period of cortical plasticity: Implications for schizophrenia.

Authors:  Hirofumi Morishita; Marija Kundakovic; Lucy Bicks; Amanda Mitchell; Schahram Akbarian
Journal:  Neurobiol Learn Mem       Date:  2015-04-04       Impact factor: 2.877

Review 2.  Targeting Oxidative Stress and Aberrant Critical Period Plasticity in the Developmental Trajectory to Schizophrenia.

Authors:  Kim Q Do; Michel Cuenod; Takao K Hensch
Journal:  Schizophr Bull       Date:  2015-06-01       Impact factor: 9.306

3.  Developmental timing and critical windows for the treatment of psychiatric disorders.

Authors:  Oscar Marín
Journal:  Nat Med       Date:  2016-10-26       Impact factor: 53.440

4.  The Fragile Brain: Stress Vulnerability, Negative Affect and GABAergic Neurocircuits in Psychosis.

Authors:  Stephan F Taylor; Tyler B Grove; Vicki L Ellingrod; Ivy F Tso
Journal:  Schizophr Bull       Date:  2019-10-24       Impact factor: 9.306

5.  Transgenerational transmission and modification of pathological traits induced by prenatal immune activation.

Authors:  U Weber-Stadlbauer; J Richetto; M A Labouesse; J Bohacek; I M Mansuy; U Meyer
Journal:  Mol Psychiatry       Date:  2016-03-29       Impact factor: 15.992

Review 6.  Adolescence as a period of vulnerability and intervention in schizophrenia: Insights from the MAM model.

Authors:  Felipe V Gomes; Millie Rincón-Cortés; Anthony A Grace
Journal:  Neurosci Biobehav Rev       Date:  2016-05-24       Impact factor: 8.989

7.  High-resolution copy number variation analysis of schizophrenia in Japan.

Authors:  I Kushima; B Aleksic; M Nakatochi; T Shimamura; T Shiino; A Yoshimi; H Kimura; Y Takasaki; C Wang; J Xing; K Ishizuka; T Oya-Ito; Y Nakamura; Y Arioka; T Maeda; M Yamamoto; M Yoshida; H Noma; S Hamada; M Morikawa; Y Uno; T Okada; T Iidaka; S Iritani; T Yamamoto; M Miyashita; A Kobori; M Arai; M Itokawa; M-C Cheng; Y-A Chuang; C-H Chen; M Suzuki; T Takahashi; R Hashimoto; H Yamamori; Y Yasuda; Y Watanabe; A Nunokawa; T Someya; M Ikeda; T Toyota; T Yoshikawa; S Numata; T Ohmori; S Kunimoto; D Mori; N Iwata; N Ozaki
Journal:  Mol Psychiatry       Date:  2016-05-31       Impact factor: 15.992

Review 8.  Altering the course of schizophrenia: progress and perspectives.

Authors:  Mark J Millan; Annie Andrieux; George Bartzokis; Kristin Cadenhead; Paola Dazzan; Paolo Fusar-Poli; Jürgen Gallinat; Jay Giedd; Dennis R Grayson; Markus Heinrichs; René Kahn; Marie-Odile Krebs; Marion Leboyer; David Lewis; Oscar Marin; Philippe Marin; Andreas Meyer-Lindenberg; Patrick McGorry; Philip McGuire; Michael J Owen; Paul Patterson; Akira Sawa; Michael Spedding; Peter Uhlhaas; Flora Vaccarino; Claes Wahlestedt; Daniel Weinberger
Journal:  Nat Rev Drug Discov       Date:  2016-03-04       Impact factor: 84.694

9.  Translational evaluation of translocator protein as a marker of neuroinflammation in schizophrenia.

Authors:  T Notter; J M Coughlin; T Gschwind; U Weber-Stadlbauer; Y Wang; M Kassiou; A C Vernon; D Benke; M G Pomper; A Sawa; U Meyer
Journal:  Mol Psychiatry       Date:  2017-01-17       Impact factor: 15.992

Review 10.  The use of antioxidant compounds in the treatment of first psychotic episode: Highlights from preclinical studies.

Authors:  Stefania Schiavone; Luigia Trabace
Journal:  CNS Neurosci Ther       Date:  2018-03-14       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.